

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LUYE PHARMA GROUP LTD.**

**绿叶制药集团有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 02186)**

**VOLUNTARY ANNOUNCEMENT**

**ACARBOSE CAPSULES PASSED NMPA'S CONSISTENCY EVALUATION**

The board of directors (the “**Board**”) of Luye Pharma Group Ltd. (the “**Company**”, together with its subsidiaries “**Group**”) is pleased to announce that the Group’s “Acarbose Capsules” (brand name “**Bei Xi**” (貝希)) has been granted approval by the National Medical Products Administration (“**NMPA**”) for passing the Consistency of Quality and Efficacy Evaluation of Generic Drugs (the “**Consistency Evaluation**”).

Bei Xi is indicated for reducing blood glucose in patients with type 2 diabetes mellitus, and reducing postprandial blood glucose in patients with impaired glucose tolerance. According to Chinese Diabetes Society, there are about 114 million diabetic patients in China (mainly with type 2 diabetes mellitus), and the prevalence of adult diabetic patients has increased significantly in recent years. According to the data from IQVIA, the market for acarbose products in China was estimated to be approximately RMB4.7 billion and Bei Xi ranked as the third most commonly used acarbose product and the ninth largest oral hypoglycemic agent in China in 2018. Bei Xi was listed in the National List of Essential Drugs and the national Medical Insurance Catalogue.

The passing of the Consistency Evaluation shows that Bei Xi is consistent with its original product in terms of quality and efficacy, and the two products are clinical alternatives. In addition, compared with acarbose tablets, Bei Xi can be administered orally without chewing and will hence improve medication compliance among middle-aged and elderly patients. The Company believes that with the passing of the Consistency Evaluation, Bei Xi will enhance its market competitiveness continually and provide better service to the Chinese diabetic patients.

By Order of the Board  
**LUYE PHARMA GROUP LTD.**  
**Liu Dian Bo**  
*Chairman*

Hong Kong, 3 June 2019

*As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive Director of the Company is Mr. SONG Rui Lin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.*